- Home
- ADCT
ADCT
ADC Therapeutics SA
as 01-21-2025 4:00pm EST
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.
| Founded: | 2011 | Country: | Switzerland |
| Employees: | N/A | City: | EPALINGES |
| Market Cap: | 224.3M | IPO Year: | 2020 |
| Target Price: | $8.00 | AVG Volume (30 days): | 709.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.68 - $6.04 | Next Earning Date: | 03-12-2025 |
| Revenue: | $70,717,000 | Revenue Growth: | -42.30% |
| Revenue Growth (this year): | 6.81% | Revenue Growth (next year): | 11.23% |
Stock Insider Trading Activity of ADC Therapeutics SA (ADCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | ADCT | 10% Owner | Dec 11 '24 | Buy | $3.05 | 200,000 | $609,000.00 | 15,616,731 | |
| Redmile Group, LLC | ADCT | 10% Owner | Dec 4 '24 | Sell | $2.07 | 25,352 | $52,478.64 | 15,566,731 |
Latest ADC Therapeutics SA News
ADCT Breaking Stock News: Dive into ADCT Ticker-Specific Updates for Smart Investing
PR Newswire
20 days ago
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan
Simply Wall St.
20 days ago
Is ADC Therapeutics SA (NYSE:ADCT) Worth US$2.0 Based On Its Intrinsic Value?
MT Newswires
22 days ago
Update: ADC Shares Rise After Company Completes Enrollment in Late-Stage Zynlonta Combination Trial
MT Newswires
23 days ago
ADC Completes Enrollment in Late-Stage Zynlonta Combination Trial
PR Newswire
23 days ago
ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma
PR Newswire
a month ago
ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma
PR Newswire
a month ago
ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma
MT Newswires
2 months ago
Top Midday Gainers
Compare ADCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADCT ADC Therapeutics SA - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.